Umoja Biopharma, a startup founded last year by Seattle biotech veteran Andy Scharenberg, announced that it has raised $53 million in a recent Series A funding round. The company will use this capital to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. Umoja’s method takes a unique approach to immunotherapy by retooling a patient’s immune system to generate cancer-fighting cells inside the body.

READ THE STORY at GeekWire »